I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Adressee" service Label No. EV 333 837 449 US under 37 CFR 1.10 on the page indicated below

and is addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on 5-9-03

BAN 0 9 THE WAY

Client Reference No.: CX-98-0028

Attorney Docket No.: 014058-009810US

## RECEIVED

MAY 1 5 2003

TECH CENTER 1600/2900

TOWNSEND and TOWNSEND and CREW LLP

By: Karen Karlin

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHEEVER et al.

Application No.: 09/493,480

Filed: January 28, 2000

For: HER-2/NEU FUSION PROTEINS

Group Director: 1642

Examiner: J. Hunt

Art Unit: 1642

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses

all the possible relevant information.

05/13/2003 MBLAKCO 00000030 201430 094

64 FC:1805

160.00 Cil



CHEEVER et al.

Application No.: 09/493,480

Page 2

This IDS is being filed on or before payment of the issue fee.

## **CERTIFICATION**

I hereby certify that no item of information contained in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully, submitted,

Keyin L. Bastian Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

MTD:mtd

SF 1457756 v1

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Reperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Application Number
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number
Filing Date
First Named Inventor

(use as many sheets as necessary)

of

Sheet

Application Number 09/493,480

Filing Date January 28, 2000

First Named Inventor Cheever, Martin A., et. al.

Art Unit 1642

Examiner Name J. Hunt TECH CENTER 1600/2

014058-009810US

			U.S. PATENT DO	OCUMENTS /	
		Document Number			
Examiner	Cite No.1	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,015,567	01-18-2000	Hudziak et al.	
	AB	US-6,333,169 B1	12-25-2001	Hudziak et al.	
	A.C.	US-App. 2002/0155527 A1	10-24-2002	/ Stuart et al	

FOREIGN PATENT DOCUMENTS

Attorney Docket Number

			<u> </u>	<b>UIVEIUITI</b>	TEITT POSSIII			
Examiner Initials*	Cite No. <sup>1</sup>	For	eign Patent Docur Number <sup>4</sup>	nent	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	AD	wo	90/14357	A)	11-29-1990			
	AE	wo	91/02062	<b>M</b> <sup>2</sup>	02-21-1991			
	AF	wo	96/18409	VA1/	06-20-1996			
	AG	EP	0474727	N B1/	07-23-1997			
	AH	wo	99/46988	<b>A</b> 1	09-23-1999			
	Al	wo	00/44899	<b>)</b> /A1	08-03-2000			
	AJ	wo	01/74855	/ A2	10-11-2001			
	AK	EP	0444181	<b>B</b> 1	10-31-2001			
			INDN	PATENT LIT	ERATURE DO	CUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue  T 2  hymber(s), publisher, city and/or country where published.						
	AL Disis et al., "Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2/neu, an Oncogenic Self-Protein", Journal of Immunology, XP-002139506: 3150-3158 (1996).							

	/	
Examiner Signature		Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.